PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q1 2016 13F Holders as of 31 Mar 2016

Type / Class
Equity / COM
Total 13F shares
60,452,860
Share change
-2,004,191
Total reported value
$263,613,080
Put/Call ratio
207%
Price per share
$4.36
Number of holders
116
Value change
-$10,036,579
Number of buys
50
Number of sells
58

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q1 2016

As of 31 Mar 2016, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 116 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 60,452,860 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, Broadfin Capital, LLC, BAKER BROS. ADVISORS LP, FMR LLC, BlackRock Fund Advisors, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, TUDOR INVESTMENT CORP ET AL, ROYCE & ASSOCIATES LP, and STATE STREET CORP. This page lists 116 institutional shareholders reporting positions in this security for the Q1 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.